Background: T-cell receptor gamma (TCR-gamma) is involved in maintaining host cell integrity and homeostasis of the human immune system. We hypothesize that polymorphism of the TCR-gamma complex may be involved in the pathogenesis of colorectal cancer.
Methods: The microsatellite markers D7S1818 and D7S2206 located within the TCR-gamma antigen locus on chromosome 7p were amplified by polymerase chain reaction, and genotypes were determined for 22 patients with early onset of colorectal cancer (<60 years old) and for 38 population-based control subjects.
Results: Genotype BC of D7S1818 (P = .049) and haplotype AC of D7S1818/D7S2206 (P < or = .003) were associated with colorectal cancer as compared with the control population (extended Fisher's exact test).
Conclusions: This study identifies a novel genetic and clinical association between TCR-gamma and early-onset colorectal cancer. Many young patients do not fulfill the criteria for hereditary colorectal cancer syndromes and are therefore not identified by established screening programs. Markers such as D7S1818 and D7S2206 may become useful in the identification of patients at risk of developing colorectal cancer and permit earlier therapeutic intervention.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1245/aso.2002.9.1.88 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
NI-3201 Is a Bispecific Antibody Mediating PD-L1-Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control.
Cancer Immunol Res
January 2025
Light Chain Bioscience - Novimmune SA, Geneva, Switzerland.
Despite advances in cancer immunotherapy, such as targeting the PD-1/PD-L1 axis, a substantial number of patients harbor tumors that are resistant or relapse. Selective engagement of T-cell co-stimulatory molecules with bispecific antibodies may offer novel therapeutic options by enhancing signal 1-driven activation occurring via T-cell receptor engagement. In this study, we report the development and preclinical characterization of NI-3201, a PD-L1×CD28 bispecific antibody generated on the κλ-body platform that was designed to promote T-cell activity and antitumor function through a dual mechanism of action.
View Article and Find Full Text PDFAddressing the unmet need in NSCLC progression with advances in second-line therapeutics.
Explor Target Antitumor Ther
November 2024
Department of Medicine, Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA.
Lung cancer is the leading cause of cancer mortality globally, with non-small cell lung cancer (NSCLC) accounting for 85% of cases. Despite advancements in first-line treatments such as immunotherapy and targeted therapies, resistance to these treatments is common, creating a significant unmet need for effective second-line therapies. This review evaluates current and emerging second-line therapeutic options for advanced or metastatic NSCLC, focusing on their efficacy and potential to improve patient outcomes.
View Article and Find Full Text PDFProtocol for assessing T cell receptor-mediated human T cell cytotoxicity.
STAR Protoc
January 2025
Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address:
Measuring the cytotoxicity of human T cells is a valuable but challenging task. We present a protocol for assessing the ability of polyclonal human T cells to kill target cells upon T cell receptor (TCR) triggering. We describe steps for preparing L and T cells for the assay and incubation of target cells with effector cells.
View Article and Find Full Text PDFAdoptive T cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation.
Immunity
December 2024
Division of Oncogenomics, Oncode institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands; Erasmus MC, Department of Genetics, Rotterdam University, Rotterdam, the Netherlands. Electronic address:
Prolonged exposure to interferon-gamma (IFNγ) and the associated increased expression of the enzyme indoleamine 2,3-dioxygenase 1 (IDO1) create an intracellular shortage of tryptophan in the cancer cells, which stimulates ribosomal frameshifting and tryptophan to phenylalanine (W>F) codon reassignments during protein synthesis. Here, we investigated whether such neoepitopes can be useful targets of adoptive T cell therapy. Immunopeptidomic analyses uncovered hundreds of W>F neoepitopes mainly presented by the HLA-A24:02 allele.
View Article and Find Full Text PDFAllosteric Changes Underlie the Outside-In Transmission of Activatory Signals in the TCR.
Immunol Rev
January 2025
Signaling Research Centers BIOSS and CIBSS, University of Freiburg, Freiburg, Germany.
Rather than being contained in a single polypeptide, and unlike receptor tyrosine kinases, the T cell receptor (TCR) divides its signaling functions among its subunits: TCRα/β bind the extracellular ligand, an antigenic peptide-MHC complex (pMHC), and the CD3 subunits (CD3γ, CD3δ, CD3ε, and CD3ζ) transmit this information to the cytoplasm. How information about the quality of pMHC binding outside is transmitted to the cytoplasm remains a matter of debate. In this review, we compile data generated using a wide variety of experimental systems indicating that TCR engagement by an appropriate pMHC triggers allosteric changes transmitted from the ligand-binding loops in the TCRα and TCRβ subunits to the cytoplasmic tails of the CD3 subunits.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!